Evaluation of a community-based memory clinic in collaboration with local hospitals to support patients with memory decline


Elbeddini A., Tayefehchamani Y., YILMAZ Z., Villegas J. J., Zhang E. Y.

JOURNAL OF TAIBAH UNIVERSITY MEDICAL SCIENCES, cilt.17, sa.2, ss.220-234, 2022 (ESCI) identifier identifier identifier

  • Yayın Türü: Makale / Tam Makale
  • Cilt numarası: 17 Sayı: 2
  • Basım Tarihi: 2022
  • Doi Numarası: 10.1016/j.jtumed.2021.05.013
  • Dergi Adı: JOURNAL OF TAIBAH UNIVERSITY MEDICAL SCIENCES
  • Derginin Tarandığı İndeksler: Emerging Sources Citation Index (ESCI), Scopus, EMBASE, Directory of Open Access Journals
  • Sayfa Sayıları: ss.220-234
  • Anahtar Kelimeler: Activities of daily living, Dementia, Deprescribing, Memory clinic, Mild cognitive impairment, ACETYLCHOLINESTERASE INHIBITORS, STOPP/START CRITERIA, ALZHEIMERS-DISEASE, COST-EFFECTIVENESS, OLDER-PEOPLE, DEMENTIA, MEDICATION, MEMANTINE, ADULTS
  • Acıbadem Mehmet Ali Aydınlar Üniversitesi Adresli: Evet

Özet

Objective: This study evaluates the role of a specialised and multidisciplinary healthcare team, including a phar-macist, in providing medication management for patients with mild cognitive impairment (MCI) and dementia, in a memory clinic. Methods: The study analysed the dataset of 102 patients of a geriatric and memory clinic in a rural area of Ontario, Canada. The case histories of the patients were reviewed a week before the clinic day and a pharmacist performed medication reconciliations. During the clinic day, cognitive tests were conducted and outcomes were discussed with the team, to create a care plan and schedule a follow-up within 3, 6 or 12 months. Results: Most patients had an average of 5 prescriptions and 2 non-prescription medications deprescribed, and 57% of patients were started on memory-related medi-cations. A total of 712 medications (p-value 0.001) were deprescribed, with 510 prescriptions and 202 non -prescription items. Out of the 712 deprescribed drugs, 374 were discontinued with no therapeutic substitutions, 202 were reduced in dosage and 136 were switched to a safer alternative. A total of 43 patients showed improved Activities of Daily Living (ADL) performance after 3 and 6 months and 68 patients showed improvement after 12 months. Conclusion: This study highlights the importance of a multidisciplinary approach in addressing drug-therapy problems, medication optimisation, and deprescription in patients with dementia. The presence of a pharmacist in the multidisciplinary team enables impactful medication optimisation and leads to improved patient outcomes. This demonstrates the value of specialised expertise in medication management for patients with dementia.